Key Points
- SVP Jean Holloway sold 7,315 shares on Dec. 3 at an average price of $45.30 for about $331,370, leaving her with 156,093 shares (a 4.48% reduction); the sale was disclosed in an SEC filing.
- Recent results beat estimates: Artivion reported $0.16 EPS vs. $0.14 expected and $113.39M in revenue (up 18.9% YoY), though the company still has a negative net margin (~-2.16%).
- Analyst and institutional backdrop: the consensus rating is a "Moderate Buy" with a $49.11 price target, and institutional investors own roughly 86.37% of the shares amid several recent stake increases.
Artivion, Inc. (NYSE:AORT - Get Free Report) SVP Jean Holloway sold 7,315 shares of the stock in a transaction dated Wednesday, December 3rd. The shares were sold at an average price of $45.30, for a total transaction of $331,369.50. Following the completion of the transaction, the senior vice president owned 156,093 shares of the company's stock, valued at $7,071,012.90. This represents a 4.48% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink.
Artivion Price Performance
AORT stock traded down $0.30 during trading hours on Friday, hitting $45.11. 7,327 shares of the stock traded hands, compared to its average volume of 428,670. The stock has a 50-day simple moving average of $43.96 and a 200 day simple moving average of $38.00. The company has a market cap of $2.14 billion, a P/E ratio of -187.96 and a beta of 1.60. Artivion, Inc. has a one year low of $21.97 and a one year high of $48.04. The company has a current ratio of 3.93, a quick ratio of 2.88 and a debt-to-equity ratio of 0.50.
Artivion (NYSE:AORT - Get Free Report) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.14 by $0.02. The company had revenue of $113.39 million during the quarter, compared to the consensus estimate of $110.71 million. Artivion had a negative net margin of 2.16% and a positive return on equity of 5.98%. Artivion's revenue was up 18.9% compared to the same quarter last year. Equities analysts forecast that Artivion, Inc. will post 0.37 earnings per share for the current year.
Institutional Inflows and Outflows
Several hedge funds have recently added to or reduced their stakes in AORT. Vanguard Group Inc. boosted its holdings in Artivion by 8.3% during the third quarter. Vanguard Group Inc. now owns 3,029,059 shares of the company's stock valued at $128,250,000 after purchasing an additional 232,424 shares in the last quarter. Wellington Management Group LLP raised its holdings in shares of Artivion by 4.1% in the 1st quarter. Wellington Management Group LLP now owns 1,727,408 shares of the company's stock worth $42,460,000 after buying an additional 67,327 shares in the last quarter. Next Century Growth Investors LLC lifted its position in shares of Artivion by 107.6% during the 1st quarter. Next Century Growth Investors LLC now owns 1,022,775 shares of the company's stock worth $25,140,000 after buying an additional 530,122 shares during the period. Bank of America Corp DE boosted its stake in Artivion by 22.8% in the 2nd quarter. Bank of America Corp DE now owns 645,070 shares of the company's stock valued at $20,062,000 after buying an additional 119,634 shares in the last quarter. Finally, Invesco Ltd. boosted its stake in Artivion by 40.8% in the 2nd quarter. Invesco Ltd. now owns 481,026 shares of the company's stock valued at $14,960,000 after buying an additional 139,370 shares in the last quarter. Institutional investors and hedge funds own 86.37% of the company's stock.
Analyst Upgrades and Downgrades
Several equities research analysts recently issued reports on AORT shares. Oppenheimer reissued an "outperform" rating and issued a $50.00 price objective on shares of Artivion in a research note on Friday, November 7th. Stifel Nicolaus raised their price target on shares of Artivion from $40.00 to $46.00 and gave the stock a "buy" rating in a report on Monday, September 29th. Wall Street Zen upgraded shares of Artivion from a "buy" rating to a "strong-buy" rating in a research note on Saturday, November 15th. Citizens Jmp upped their price objective on shares of Artivion from $47.00 to $53.00 and gave the stock a "market outperform" rating in a report on Friday, November 7th. Finally, Citigroup reiterated an "outperform" rating on shares of Artivion in a report on Friday, October 10th. Seven investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and a consensus price target of $49.11.
Read Our Latest Report on Artivion
Artivion Company Profile
(
Get Free Report)
Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
